Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07606625 · ClinicalTrials.gov registry record · Phase 4
Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
A Phase 4 study, sponsored by University of California, Berkeley.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT07606625 is a Phase 4 study that is actively recruiting participants, run by University of California, Berkeley. The registered enrollment target is 65 participants.
The verdict
NCT07606625, a Phase 4 study, is actively recruiting participants, sponsored by University of California, Berkeley.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).
Interventions
- DRUG Varenicline 0.03Mg/Spray Nasal Soln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2026-03-06 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07606625
The ClinicalTrials.gov registry entry for NCT07606625 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Berkeley, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Varenicline 0.03Mg/Spray Nasal Soln is the first listed.
NCT07606625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07606625 about?
NCT07606625 is a clinical study titled "Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment". The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).
What is the current status of trial NCT07606625?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2026-03-06. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT07606625?
The interventions under investigation include: Varenicline 0.03Mg/Spray Nasal Soln (DRUG).
Who is sponsoring clinical trial NCT07606625?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.